S&P Biotech ETF (CURE) – Global X ETFs Australia
Australia
Search

CURE

S&P Biotech ETF

Invest in CURE Request Research
Overview Performance Holdings & Characteristics Research Documents Announcements FAQs

Reasons to Consider CURE

High Growth Potential

Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.

Risk Controls

Limit company-specific risks, such as risk of testing failures or higher than anticipated development costs, by using an equal weighting across many biotechnology companies.

Targeted Exposure

CURE provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

Product Information As of 16 May 2024

Inception Date 8 Nov 2018
Management Costs (% p.a.) 0.45
Currency Hedged No
Domicile Australia
Legal Form Managed Investment Scheme
SMSF Eligible Yes

NAV Information As of 16 May 2024

NAV/Unit (A$) 47.35900000
Currency (NAV) AUD
Shares Outstanding 844,012
AUM (A$) 39,971,529.57
NAV History File View

Product Summary

The Global X S&P Biotech ETF (CURE) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Product Objective

The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.

Trading Details

Ticker CURE
Bloomberg Code CURE AU Equity
ISIN AU0000028110
Trading Hours 10:00AM – 4:00PM

Management & Administration

Issuer Global X Management (AUS) Limited
Custodian The Hongkong and Shanghai Banking Corporation Limited, Sydney Branch
Registrar Computershare Investor Services Pty Limited

Benchmark Information

Benchmark S&P Biotechnology Select Industry Index
Provider S&P Indices
Ticker SPSIBIN

Distributions As of 30 Apr 2024

12-Month Yield 0.00%
12-Month Franking Level 0.00%
Distribution Frequency Annually
Distribution History View

Performance Table As of 16 May 2024

Total Return (Fund) Total Return (Benchmark) Tracking Difference Tracking Error
1 Month 3.69% 3.76% -0.07% 0.03%
3 Months -2.99% -2.83% -0.16% 0.37%
1 Year 8.40% 9.28% -0.87% 0.54%
3 Year p.a. -5.45% -5.15% -0.30% 1.00%
5 Year p.a. 2.49% 2.90% -0.42% 0.86%
10 Year p.a. -- -- -- --
Since Inception p.a. 3.10% 3.53% -0.43% 0.84%

Top Holdings As of 17 May 2024

Full Holdings (.xlsx)
Net Assets (%) Name SEDOL Market Price (Local) Shares Held Market Value (A$)
2.74 NOVAVAX INC BJDQXG4 14.40 50,838 1,096,483
1.73 ALPINE IMMUNE SC BYX38M1 64.96 7,088 689,638
1.34 MODERNA INC BGSXTS3 132.68 2,689 534,377
1.29 TWIST BIOSCIENCE BGKG6G7 46.50 7,375 513,649
1.27 CRINETICS PHARMA BDD19F8 51.91 6,552 509,420
1.26 NATERA INC BYQRG48 108.50 3,111 505,570
1.26 REVOLUTION MEDIC BL71K91 38.99 8,591 501,705
1.20 BLUEPRINT MEDICI BWY52P3 106.64 3,002 479,493
1.19 AMGEN INC 2023607 314.72 1,012 477,041
1.16 UNITED THERAPEUT 2430412 272.22 1,140 464,811
1.15 BIOCRYST PHARM 2100362 6.47 47,427 459,601
1.15 IMMUNITYBIO INC BNSP0B8 7.75 39,590 459,556
1.13 PTC THERAPEUTICS B17VCN9 34.03 8,892 453,224
1.13 HALOZYME THERAPE 2975098 45.39 6,639 451,351
1.12 DYNE THERAPEUTIC BN15WD1 28.75 10,405 448,055
1.11 BRIDGEBIO PHARMA BK1KWG8 31.04 9,561 444,505
1.11 ROIVANT SCIENCES BMW4NZ9 11.41 25,942 443,343
1.11 SAREPTA THERAPEU B8DPDT7 132.74 2,228 442,964
1.11 VERTEX PHARM 2931034 440.64 670 442,191
1.08 TG THERAPEUTICS B828K63 17.42 16,512 430,823
1.08 VAXCYTE INC BKPVGH6 75.45 3,812 430,788
1.07 BIOGEN INC 2455965 230.04 1,241 427,589
1.07 CEREVEL THERAPEU BMVMJ12 42.35 6,717 426,069
1.06 GERON CORP 2370381 3.90 72,849 425,539
1.06 NEUROCRINE BIOSC 2623911 141.91 1,990 422,977
1.05 ALNYLAM PHARMACE B00FWN1 151.22 1,849 418,791
1.04 REGENERON PHARM 2730190 967.98 286 414,652
1.03 IMMUNOVANT INC BJRFSB7 31.48 8,743 412,236
1.00 VIKING THERAPEUT BQQG1V1 69.06 3,860 399,268
1.00 DENALI THERAPEUT BD2B4V0 20.24 13,140 398,343
0.99 EXELIXIS INC 2576941 21.23 12,475 396,681
0.99 KRYSTAL BIOTECH BD6JX35 163.78 1,612 395,437
0.98 INCYTE CORP 2471950 56.86 4,616 393,119
0.97 RHYTHM PHARMACEU BF2YWG4 39.17 6,606 387,564
0.95 ABBVIE INC B92SR70 164.35 1,549 381,305
0.95 IDEAYA BIOSCIENC BK0VHF6 41.53 6,081 378,258
0.95 CYTOKINETICS INC BBBSBJ5 59.92 4,214 378,196
0.94 GILEAD SCIENCES 2369174 67.86 3,688 374,849
0.94 INSMED INC 2614487 25.10 9,959 374,404
0.93 ARDELYX INC BN89V40 7.79 31,883 372,004
0.93 BIOMARIN PHARMAC 2437071 76.97 3,224 371,679
0.93 VERICEL CORP BSBMN89 47.61 5,207 371,310
0.91 SPRINGWORKS THER BGMGM89 44.77 5,425 363,779
0.91 INTELLIA THERAPE BYZM6C2 26.17 9,245 362,378
0.90 CATALYST PHARMAC B1G7Q03 16.40 14,707 361,259
0.90 EXACT SCIENCES 2719951 51.95 4,615 359,094
0.89 NUVALENT INC-A BMVBZD3 72.64 3,283 357,189
0.89 DYNAVAX TECHNOLO BRJZSK0 11.28 21,086 356,250
0.89 ALTIMMUNE INC BFY7DC4 8.90 26,666 355,467
0.89 IONIS PHARMACEUT BDJ0LS6 37.62 6,298 354,873
0.88 SYNDAX PHARMACEU BN7Q7R7 20.92 11,277 353,351
0.88 MADRIGAL PHARMAC BD59BS7 217.17 1,085 352,924
0.88 RECURSION PHAR-A BM9FJ13 9.51 24,760 352,681
0.88 AGIOS PHARMACEUT BCBVTX1 35.00 6,683 350,341
0.88 ULTRAGENYX PHARM BJ62Z18 42.61 5,483 349,930
0.87 ROCKET PHARMACEU BDFKQ07 23.40 9,941 348,415
0.87 ALKERMES PLC B3P6D26 24.46 9,472 347,016
0.87 CELLDEX THERAPEU BJLV8T9 39.94 5,783 345,949
0.86 PROTAGONIST THER BDCBCD8 31.94 7,227 345,736
0.85 KYMERA THERAPEUT BMPRZV5 35.60 6,371 339,710
0.85 ARCUTIS BIOTHERA BKX9VD3 9.12 24,849 339,434
0.83 VERA THERAPEUTIC BL55460 41.94 5,281 331,738
0.82 VERACYTE INC BFTWZY0 23.40 9,322 326,720
0.81 MORPHIC HOLDING BK8M4J4 32.45 6,671 324,233
0.81 KURA ONCOLOGY IN BYZD465 22.98 9,404 323,678
0.80 PROTHENA CORP PL B91XRN2 23.39 9,168 321,186
0.80 AMICUS THERAPEUT B19FQ48 9.50 22,526 320,523
0.79 INHIBRX INC BK1MBC3 34.49 6,102 315,222
0.78 ARROWHEAD PHARMA BYQBFJ8 25.00 8,283 310,155
0.77 IRONWOOD PHARMAC B3MZ6K5 6.64 30,751 305,829
0.76 ARCELLX INC BPCJ1Q2 52.79 3,830 302,832
0.75 MIRUM PHARMACEUT BJDX8Y8 24.75 8,045 298,231
0.73 CRISPR THERAPEUT BDHF4K6 55.67 3,511 292,754
0.73 KEROS THERAPEUTI BM7V485 53.99 3,611 292,006
0.71 APELLIS PHARMACE BYTQ6X1 42.00 4,496 282,831
0.70 ADMA BIOLOGICS I B9NSBM2 9.06 20,613 279,718
0.69 MYRIAD GENETICS 2614153 24.61 7,529 277,524
0.69 BIOMEA FUSION IN BNKF6N0 12.78 14,453 276,656
0.69 AKERO THERAPEUTI BK7Y2V9 20.73 8,886 275,903
0.69 IOVANCE BIOTHERA BF0DMK7 10.43 17,647 275,681
0.69 BIOHAVEN LTD BPLZ7S5 38.45 4,779 275,223
0.68 VIRIDIAN THERAPE BMDH2B6 14.63 12,354 270,709
0.67 ARCUS BIOSCIENCE BDZT9Y9 17.46 10,262 268,366
0.66 BEAM THERAPEUTIC BK6L288 23.79 7,382 263,039
0.66 ACADIA PHARMACEU 2713317 14.85 11,820 262,903
0.65 AVIDITY BIOSCIEN BMWHPY1 28.72 6,072 261,197
0.63 DECIPHERA PHARMA BZ1LFB2 25.45 6,593 251,317
0.61 CAREDX INC BP3YM74 14.78 11,021 243,976
0.60 COGENT BIOSCIENC BLR6XK8 7.47 21,296 238,270
0.58 XENCOR INC BGCYWN8 22.46 6,930 233,128
0.56 C4 THERAPEUTICS BKX9NQ0 5.97 25,188 225,226
0.56 SCHOLAR ROCK HOL BFZQ0L8 14.32 10,446 224,050
0.55 SOLENO THERAPEUT BL6JK96 45.66 3,207 219,324
0.55 AVID BIOSERVICES BFMZ4W7 9.20 15,879 218,807
0.54 ARCTURUS THERAPE BKC9SX3 30.50 4,731 216,124
0.54 EDITAS MEDICINE BZ8FPH3 5.89 24,348 214,798
0.53 SAGE THERAPEUTIC BP4GNK9 12.01 11,856 213,271
0.51 CABALETTA BIO IN BK5MWR1 12.62 10,708 202,404
0.49 VIR BIOTECHNOLOG BK4PZ38 9.93 13,273 197,410
0.49 REPLIMUNE GROUP BDDVW37 6.72 19,399 195,254
0.48 SANA BIOTECHNOLO BMFJJ97 8.55 14,983 191,874
0.47 89BIO INC BK1K484 8.97 13,957 187,515
0.45 4D MOLECULAR THE BKLXFX5 25.64 4,700 180,496
0.45 TRAVERE THERAPEU BLFGJD5 6.69 17,983 180,194
0.40 ZENTALIS PHARMAC BMQ5T49 11.96 9,004 161,294
0.40 APOGEE THERAPEUT BM9HHL5 53.75 1,998 160,851
0.38 MANNKIND CORP BF081J4 4.59 22,119 152,065
0.37 DISC MEDICINE IN BMGJZJ8 31.92 3,108 148,592
0.37 NURIX THERAPEUTI BMVLGP2 15.40 6,388 147,345
0.35 DAY ONE BIOPHARM BLB0YH0 16.03 5,838 140,168
0.34 RELAY THERAPEUTI BN2R582 6.51 14,021 136,713
0.34 FATE THERAPEUTIC BCZS820 4.14 22,045 136,698
0.34 ANAVEX LIFE SCIE BYTYP72 4.50 20,241 136,426
0.33 SUMMIT THERAPEUT BMTVQS7 4.51 19,647 132,716
0.33 REGENXBIO INC BZ0G875 16.01 5,434 130,305
0.32 OLEMA PHARMACEUT BMZ4LN0 9.66 8,904 128,829
0.32 KINIKSA PHARMA-A BD0MGM0 20.11 4,256 128,193
0.31 VERVE THERAPEUTI BNKGXX2 6.38 13,039 124,599
0.27 ALLOGENE THERAPE BFZNYB7 3.01 23,739 107,024
0.26 CULLINAN THERAPE BM90J52 23.81 2,932 104,562
0.26 ANAPTYSBIO INC BDRW1L7 25.47 2,740 104,528
0.26 MIMEDX GROUP INC B1Z3TW5 7.89 8,709 102,919
0.22 CARIBOU BIOSCIEN BNYJR68 3.59 16,358 87,958
0.20 MACROGENICS INC BFDV8K0 5.12 10,656 81,718
0.19 TANGO THERAPEUTI BP2P6L0 7.79 6,647 77,556
0.17 ALECTOR INC BJ4LDC4 5.49 8,327 68,472
0.17 ASTRIA THERAPEUT BMYRFN8 9.43 4,729 66,793
0.12 VOYAGER THERAPEU BY7RB53 8.63 3,602 46,559
0.11 CARGO THERAPEUTI BQHN2F2 21.34 1,438 45,963
0.11 ARS PHARMACEUTIC BMCR7V2 9.10 3,371 45,946
0.11 ORIC PHARMACEUTI BKVDFF7 9.02 3,358 45,367
0.11 MERSANA THERAPEU BF3NP05 2.58 11,131 43,014
0.07 SCILEX HOLDING C BLKFRT9 0.87 21,910 28,550
0.05 AVITA MEDICAL IN BMX0JN6 7.92 1,559 18,494
Holdings are subject to change.

Sector Breakdown As of 17 May 2024

Sector Weight (%)
Health Care 99.8
Other/Cash 0.2

Country Breakdown As of 17 May 2024

Country Weight (%)
United States 97.4
Ireland 1.7
Switzerland 0.7
Other/Cash 0.2

Research

Investing in Pharma: The Drug Lifecycle

Read More

Charting Disruption: Medical Breakthroughs

Read More

AI Applications in Healthcare: From Drug Discovery to Patient Care

Read More

Documents

FAQs

  • What is biotechnology?

    Biotechnology includes companies primarily engaged in the research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. It includes companies specialising in protein-based therapeutics to treat human diseases. It excludes companies manufacturing products using biotechnology but without a healthcare application. Biotechnology is a sub-industry of the healthcare sector.

  • How does biotechnology differ from healthcare?

    Biotechnology is a sub-industry within the Healthcare sector.

    The Healthcare sector refers to all those industries involved in providing goods and services to manage the health needs of individuals and populations. There are two main groupings within the healthcare sector according to the Global Industry Classification Standards (GICS) including:

    Healthcare equipment and services

    Pharmaceuticals, biotechnology, and Life Sciences.

  • How are companies in CURE weighted?

    Companies in CURE are equally weighted (subject to liquidity constraints), meaning each holding makes up the same portion of the portfolio at each quarterly rebalance and therefore contributes equally to overall performance.

    The choice of an equal weighting scheme provides investors exposure to the overall sector and allows all stocks to contribute equally to returns. Large-cap stocks do not dominate as they do where holdings are weighted by market capitalisation.

  • Why use CURE for biotechnology exposure?

    While biotechnology can be a lucrative space, it can also be high risk. The drug development process is very lengthy with high failure rates and it is an area that is sensitive to government policy. Using an ETF like CURE not only spreads the risk over many biotechnology companies but reduces the single stock risk further by using an equal weight method.

    CURE enables investors to access the growth in the U.S. biotechnology sector, without having to pick individual winners.

  • How can you use CURE in a portfolio?

    CURE may be used as a tool for expressing long-term strategic or short-term tactical views on the biotechnology sub-industry.

    CURE can also aid portfolio diversification via investment in a sector that is underrepresented in the Australian market.

Global X Management (AUS) Limited (“Global X”) (Australian Financial Services Licence Number 466778, ACN 150 433 828) is the product issuer. Offers of interests in any retail product will only be made in, or accompanied by, a Product Disclosure Statement (PDS). In respect of each retail product, Global X has prepared a target market determination (TMD). Each PDS and TMD is available at www.globalxetfs.com.au. The information on this website is general in nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information, you should consider the appropriateness of the information having regard to your objectives, financial situation or needs and consider seeking independent financial, legal, tax and other relevant advice having regard to your particular circumstances. Any investment decision should only be made after obtaining and considering the relevant PDS and TMD. Investments in any product issued by Global X are subject to investment risk, including possible delays in repayment and loss of income and principal invested. The value or return of an investment will fluctuate and an investor may lose some or all of their investment. Past performance is not a reliable indicator of future performance.

Back to Top
git